The rise of full-body MRI scans has been framed as a victory for consumer empowerment. Skip the referrals. Skip the waiting. Pay out of pocket and finally see what is happening inside your body, before it’s too late.
For many, especially women, these scans are compelling. They offer agency in a healthcare system that often feels slow, dismissive, and reactive, rather than preventive. What many women would be surprised to learn, however, is despite the name, many full-body MRI scans do not reliably screen for breast cancer, the most common cancer in women.
Women make roughly 80% of healthcare purchasing decisions in the United States. They spend more out of pocket than men and are significantly more likely to engage in preventive care, before symptoms appear. Women are also, ironically, the same population driving the growth of direct-to-consumer healthcare, from blood testing and longevity clinics to wearables and these “full-body” scans.
The assumption most consumers make is simple. If a scan purports to image the entire body, it must include the breasts. These scans assess the brain, spine, liver, kidneys, and reproductive organs. These scans may produce reports that say everything looks normal. They may even use language like “all clear.”
What they cannot do, in many cases, is detect early breast cancer.
Not a nuance
This is not a subtle technical nuance. Breast-specific MRI requires precise conditions to be effective: dedicated breast coils, prone positioning, contrast enhancement, and high spatial resolution. Full body MRI scans are optimized for speed and coverage, not for the detailed imaging that breast tissue requires. As a result, these scans can miss small or early lesions, particularly in dense breasts, which affect nearly half of all women over 40 and are common in younger women.
Radiologists understand this distinction. The companies selling these scans are aware of this as well, and they even include this disclosure in the fine print. However, the average consumer often isn’t aware.
The issue is compounded by how reassurance, or an “all clear” report, can affect consumer behavior. Many women already avoid routine mammography because of fear, discomfort, radiation concerns, or prior negative experiences. Dr. Marty Makary, FDA Commissioner, pointed out in an interview recently that roughly 40% of women skip mammograms for these reasons. When those same women receive a clean full-body scan, even with disclaimers advising continued screening, the psychological effect is powerful. Relief tends to override caution.
False sense of security
This is not about bad intentions. It is about predictable human behavior. If a woman believes she has just paid for a comprehensive “full body” scan, she may deprioritize another screening that feels redundant or stressful. When the scan she relied on was never capable of evaluating her breasts in the first place, the sense of security becomes misleading.
The way these scans are marketed makes the problem worse. Much of the language, imagery, and cultural framing around preventive imaging has been shaped by the same audience that dominates wellness and longevity media more broadly: The male “biohacker.” The optimization-focused technologist. The podcast-listening early adopter. This is not inherently negative, but it reflects who has historically held influence in venture-backed healthcare.
Women, despite being the primary buyers, often remain peripheral in how these tools are designed and explained.
The result is a mismatch between who the product is built for and who is actually using it. Breast cancer is the most commonly diagnosed cancer in women, and its incidence has been rising, including among younger patients who fall outside traditional screening guidelines. These are precisely the women drawn to proactive, cash-pay healthcare. Yet the most visible preventive imaging offerings do not adequately address the risk they face most.
Valuable in some contexts
To be clear, full-body MRI scans are not useless. I underwent one recently and not only enjoyed my experience, but was relieved upon receiving my report. These scans can surface certain conditions and provide valuable information in specific contexts. The issue is not that they exist, but that they are positioned as comprehensive reassurance without clearly communicating their limits.
If a scan cannot screen for breast cancer, that fact should be explicit, prominent, and impossible to miss. Not buried in fine print, softened by marketing language, or deferred to a follow-up conversation after purchase.
Healthcare innovation often celebrates disruption while reproducing old blind spots. Women are encouraged to take control of their health, to invest in prevention, and to advocate for themselves. When they do, they deserve tools that are designed with their bodies in mind and explanations that respect their intelligence.
That gap is why I founded BeSound. Full-body MRI scans are a real step forward, but women also need specific imaging for the cancer they are most likely to develop. Breast cancer is the most commonly diagnosed cancer in women, and it should not require the cost of a full-body scan to screen for it. When dedicated breast imaging is done well and priced far lower, it becomes something women can actually access and repeat, not a one-time splurge meant to buy peace of mind.
Preventive imaging should be honest about what it can and cannot do. It should prioritize conditions that are common, deadly, and detectable when found early. It should not rely on the comfort of a broad label like “full body” to imply coverage that does not exist.
Peace of mind is not a marketing outcome. It is a medical one, and it only holds value when it is grounded in reality.